AI Science Tracker
EN

Department of Nephrology, The First Hospital of Jilin University, Changchun, China

1 discovery from 2022

Discoveries

Identification of diagnostic gene biomarkers and immune infiltration in patients with diabetic kidney disease using machine learning strategies and bioinformatic analysis.

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: LASSO, SVM-RFE and random forest selected DUSP1 and PRKAR2B from training expression cohorts; separate GEO cohorts and kidney-tissue IHC were used for validation. Validation AUCs were 0.789 and 0.709, below training values. This is a narrow retrospective biomarker finding, not clinical diagnostic deployment.

Technology: Full text specifies the learned operation and how it supports the represented result.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Full text specifies the learned operation and how it supports the represented result.
Limitation / still unknown
Results are limited to the reported models, cohorts, datasets or experiments; broader generalization and clinical or operational benefit were not established.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2022.918657/full

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.